LeMaitre Vascular exec exercises options, sells shares

LeMaitre Vascular senior vice president Trent G. Kamke exercised stock options and sold the resulting shares.

Rhea-AI Filing Summary

LeMaitre Vascular senior vice president Trent G. Kamke exercised stock options and sold the resulting shares. He exercised options for 2,625 shares of common stock at an exercise price of $35.48 per share, then sold 2,625 shares at $108.50 per share, leaving 6,677 shares owned directly.

Insider Trade Summary

Exercise and Sale: 2,625 shares ($192K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Kamke Trent G

Role Senior V. P., Operations

Sold 2,625 shs ($285K)

Approx. gross sale proceeds $285K

Approx. exercise cost $93K

Approx. pre-tax spread $192K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,625	$0.00	$0.00
Exercise	Common Stock	2,625	$35.48	$93K
Sale	Common Stock	2,625	$108.50	$285K

Holdings After Transaction: Stock Option (Right to Buy) — 1,353 contracts (Direct); Common Stock — 6,677 shares (Direct)

Footnotes (2)

1. F1. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.
2. F2. This option is fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did LMAT executive Trent G. Kamke report?

Trent G. Kamke reported exercising options for 2,625 shares of LeMaitre Vascular common stock and selling 2,625 shares. The transactions occurred on March 11, 2026 and reflect an exercise-and-sell pattern rather than a net purchase of additional shares.

At what prices did the LMAT insider option exercise and share sale occur?

The options were exercised at an exercise price of $35.48 per share, while the subsequent sale of 2,625 common shares occurred at $108.50 per share. This shows the conversion of a derivative grant into cash at a significantly higher market price.

How many LMAT shares does Trent G. Kamke hold after these transactions?

After exercising and then selling 2,625 shares, Trent G. Kamke directly holds 6,677 shares of LeMaitre Vascular common stock. This reflects his remaining equity position as reported in the Form 4 following the March 11, 2026 transactions.

What type of derivative security did the LMAT executive exercise?

The executive exercised a stock option, described as a “Stock Option (Right to Buy)” covering 2,625 underlying shares of LeMaitre Vascular common stock. The option was fully vested and exercisable, according to the accompanying footnote disclosure in the filing.

Does the LMAT Form 4 show an open-market sale by the insider?

Yes. The Form 4 reports an open-market sale of 2,625 shares of LeMaitre Vascular common stock at $108.50 per share. This followed the same-day exercise of options for the same number of shares, forming an exercise-and-sell transaction sequence.

What do the footnotes in the LMAT Form 4 clarify about these transactions?

The footnotes explain that the common shares were acquired upon exercise of options reported in the derivative table and state that the option was fully vested and exercisable. They confirm the linkage between the derivative exercise and the common stock acquisition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/13/2026 - 04:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kamke Trent G

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR , INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior V. P., Operations

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		M		2,625(1)	A	$35.48	9,302	D
Common Stock	03/11/2026		S		2,625	D	$108.5	6,677	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.48	03/11/2026		M			2,625	12/20/2019(2)	12/20/2026	Common Stock	2,625	$0	1,353	D

Explanation of Responses:

1. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.

2. This option is fully vested and exercisable.

	/s/ Laurie A. Churchill, Attorney-in-fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.